Abbott Laboratories stock gains 2.6% as Q3 growth sharpens outlook

Published on 11/02/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Abbott Laboratories stock trades higher after management reported balanced third-quarter growth. Investors now focus on execution against tighter full-year adjusted EPS guidance.

Abbott's Growth And Outlook

Third-quarter comparable sales increased 7.0 percent, while reported sales rose 14.5 percent.
Management tightened full-year adjusted EPS guidance to USD 5.50 to USD 5.55.
Medical Devices and Diagnostics remain central to Abbott's growth execution.

Abbott Laboratories, US0028241000, Illustration mit AI erstellt.

Abbott Laboratories reported stronger third-quarter operating momentum on October 21, 2026, according to the Abbott Newsroom. Comparable sales increased 7.0 percent, while reported sales rose 14.5 percent in the quarter ended September 30.

The company said adjusted diluted earnings per share increased 9.2 percent to USD 1.42. GAAP diluted EPS was USD 0.53, reflecting specified items that included intangible amortization, legal settlements, acquisition-related costs and restructuring actions.

Growth Broadens Across Segments

Medical Devices delivered comparable sales growth of 7.8 percent, led by a 15.5 percent increase in Electrophysiology. Abbott attributed the performance in part to rising adoption of its Volt pulsed-field ablation catheter.

Nutrition returned to positive growth, with sales up 4.9 percent on a comparable basis. Abbott also highlighted new product approvals and launches, including Libre Duo 10 Day, TactiFlex Duo and SimpleScreen CRC. Management expects to launch Libre Duo 10 Day in the United States in December.

Guidance Sets The Next Test

Abbott tightened its full-year adjusted diluted EPS guidance to USD 5.50 to USD 5.55 while reaffirming the midpoint. The company projects full-year comparable sales growth of approximately 6.0 percent and expects fourth-quarter adjusted diluted EPS of USD 1.62 to USD 1.67.

Abbott Laboratories stock traded at EUR 97.02 on Lang & Schwarz at 16:30 CET on Monday, November 2, 2026, 1.87 percent above the Xetra close of Friday, October 30, at EUR 95.24. The Xetra closing price is shown by Yahoo Finance. Compared with the EUR 94.56 quote at 10:40 CET in the previous report, the current Lang & Schwarz price is 2.60 percent higher.

For investors tracking the broader market, Abbott's setting remains linked to the S&P 500.

Investors will watch fourth-quarter delivery against the revised earnings range, particularly in Medical Devices and Diagnostics, while Abbott advances its product pipeline and integrates Exact Sciences. The real-time quote of Abbott Laboratories stock provides the latest trading indication.

Abbott Laboratories stock at a glance